Cite
HARVARD Citation
Mi, J. et al. (2023). Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). Journal of clinical oncology. 41 (6), pp. 1275-1284. [Online].